Combination treatment in the management of type 2 diabetes: Focus on vildagliptin and metformin as a single tablet

Vascular Health and Risk Management

Volumn 4, Issue 3, 2008, Pages 481-492

  Halimi, Serge ^a   Schweizer, Anja ^b   Minic, Biljana ^b   Foley, James ^b   Dejager, Sylvie ^c  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b NOVARTIS PHARMA AG   (Switzerland)

^c NOVARTIS PHARMA K K   (Japan)

Author keywords

Dipeptidyl peptidase 4; Eucreas ; GLP 1; HbA1c; Incretin hormones; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ANTIDIABETIC AGENT; BIGUANIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EUCREAS; GLUCAGON; GLUCAGON LIKE PEPTIDE 1 AGONIST; HEMOGLOBIN A1C; INSULIN; METFORMIN; METFORMIN PLUS VILDAGLIPTIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SULFONYLUREA; VILDAGLIPTIN;

ADD ON THERAPY; ANOREXIA; BODY WEIGHT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DIET THERAPY; DISEASE COURSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG RESPONSE; DRUG TISSUE LEVEL; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; GLUCAGON RELEASE; GLYCEMIC CONTROL; GOLD STANDARD; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; LACTIC ACIDOSIS; LIFESTYLE MODIFICATION; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET CELL FUNCTION; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PRACTICE GUIDELINE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; TASTE AVERSION; WEIGHT GAIN;

ADAMANTANE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DISEASE PROGRESSION; DRUG COMBINATIONS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; ISLETS OF LANGERHANS; METFORMIN; NITRILES; PYRROLIDINES; TABLETS; TREATMENT OUTCOME;

EID: 47849106717     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (84)

1. UKPDS 34. 1998. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet, 352:854-65.
2. Ahren B. 2006. Glucagon secretion in relation to insulin sensitivity in healthy subjects. Diabetologia, 49:117-22.
3. Ahren B, Gomis R, Standl E, et al. 2004a. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care, 27:2874-80.
4. Ahren B, Landin-Olsson M, Jansson PA, et al. 2004b. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab, 89:2078-84.
5. Ahren B, Pacini G, Foley JE, et al. 2005. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care, 28:1936-40.
6. Ahren B, Pacini G, Tura A, et al. 2007. Improved meal-related insulin processing contributes to the enhancement of B-Cell Function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes. Horm Metab Res, 39:826-9.
7. Ahrén B, Pratley RE, Soubt M, et al. 2008. Clinical measures of islet function: usefulness to characterize defects in diabetes. Curr Diabetes Rev (in Press).
8. Ayalasomayajula SP, Dole K, He YL, et al. 2007. Evaluation of the potential for steady-state pharmacokinetic interaction between vildagliptin and simvastatin in healthy subjects. Curr Med Res Opin, 23:2913-20.
9. Azuma K, Radikova Z, Mancino J, et al. 2007. Measurements of islet function and glucose metabolism with the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes. J Clin Endocrinol Metab.
10. Bailey CJ, Turner RC. 1996. Metformin. N Engl J Med, 334:574-9.
11. Balas B, Baig MR, Watson C, et al. 2007. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab, 92:1249-55.
12. Balkrishnan R, Rajagopalan R, Camacho FT, et al. 2003. Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: a longitudinal cohort study. Clin Ther, 25:2958-71.
13. Bangalore S, Kamalakkannan G, Parkar S, et al. 2007. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med, 120:713-19.
14. Bolli G, Dotta F, Rochotte E, et al. 2008. Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study. Diabetes Obes Metab, 10:82-90.
15. Bosi E, Camisasca RP, Collober C, et al. 2007a. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care, 30:890-5.
16. Bosi E, Shao Q, Cohen SE. 2007b. Improved blood pressure (BP) lowering in hypertensive patients (pts) with type 2 diabetes (T2DM) with vildagliptin combined with metformin compared with metformin alone. Diabetes, 56:A549.
17. Brown JB, Nichols GA, Perry A. 2004. The burden of treatment failure in type 2 diabetes. Diabetes Care, 27:1535-40.
18. Brown JB, Pedula K, Barzilay J, et al. 1998. Lactic acidosis rates in type 2 diabetes. Diabetes Care, 21:1659-63.
19. Burkey BF, Russell M, Wang K, et al. 2006. Vildagliptin displays slow tight-binding to dipeptidyl peptidase (DPP)-4, but not DPP-9 or DPP-9, Diabetologia, 49:477-8.
20. Butler AE, Janson J, Bonner-Weir S, et al. 2003. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes, 52:102-10.
21. Consoli A, Gomis R, Halimi S, et al. 2004. Initiating oral glucose-lowering therapy with metformin in type 2 diabetic patients: an evidence-based strategy to reduce the burden of late-developing diabetes complications. Diabetes Metab, 30:509-16.
22. Cook MN, Girman CJ, Stein PP, et al. 2007. Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with Type 2 diabetes in UK primary care. Diabet Med, 24:350-8.
23. Cramer JA. 2004. A systematic review of adherence with medications for diabetes. Diabetes Care, 27:1218-24.
24. DeFronzo RA, Goodman AM. 1995. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med, 333:541-9.
25. Dejager S, Razac S, Foley JE, et al. 2007. Vildagliptin in drug-naive patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm Metab Res, 39:218-23.
26. Dezii CM, Kawabata H, Tran M. 2002. Effects of once-daily and twice-daily dosing on adherence with prescribed glipizide oral therapy for type 2 diabetes. South Med J, 95:68-71.
27. Donnelly LA, Doney AS, Hattersley AT, et al. 2006. The effect of obesity on glycaemic response to metformin or sulphonylureas in Type 2 diabetes. Diabet Med, 23:128-33.
28. Dunning BE, Ligueros-Saylan M, D'Alessio DA, et al. 2006. Differential effects of DPP-4 inhibition on incretin hormone levels in drug-naive and metformin-treated patients with type 2 diabetes. Diabetologia, 49110-11.
29. Duttaroy A, Voelker F, Zhang X, et al. 2005. The DPP-4 inhibitor vildagliptin increases pancreatic beta cell mass in rodents. Diabetologia, 48:A178.
30. El Ouaghlidi A, Rehring E, Holst JJ, et al. 2007. The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion. J Clin Endocrinol Metab, 92:4165-71.
31. Fonseca V, Schweizer A, Albrecht D, et al. 2007. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia, 50:1148-55.
32. Garber AJ, Camisasca RP, Jauffret S, et al. 2007a. Efficacy and tolerability of vildagliptin added to a sulfonylurea (SU) in patients with type 2 diabetes (T2DM). Diabetes, 56:A134.
33. Garber AJ, Schweizer A, Baron MA, et al. 2007b. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab, 9:166-74.
34. Golay A. 2007. Metformin and body weight. Int J Obes (Lond).
35. Goodarzi MO, Bryer-Ash M. 2005. Metformin revisited: re-evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents. Diabetes Obes Metab, 7:654-65.
36. Grant RW, Devita NG, Singer DE, et al. 2003. Polypharmacy and medication adherence in patients with type 2 diabetes. Diabetes Care, 26:1408-12.
37. Green BD, Irwin N, Duffy NA, et al. 2006. Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1. Eur J Pharmacol, 547:192-9.
38. Guillausseau PJ. 2003. Influence of oral antidiabetic drugs compliance on metabolic control in type 2 diabetes. A survey in general practice. Diabetes Metab, 29:79-81.
39. Halum S. 2006. Metformin: 50 years old, fit as a fiddle, and indispensable for its pivotal role in type 2 diabetes management. Diabetes Metab, 32:555-6.
40. He YL, Sabo R, Riviere GJ, et al. 2007a. Effect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Curr Med Res Opin, 23:1131-8.
41. He YL, Sabo R, Sunkara G, et al. 2007b. Evaluation of pharmacokinetic interactions between vildagliptin and digoxin in healthy volunteers. J Clin Pharmacol, 47:998-1004.
42. He YL, Sadler BM, Sabo R, et al. 2007c. The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers. Clin Pharmacokinet, 46:787-802.
43. He YL, Serra D, Wang Y, et al. 2007d. Pharmacokinetics and pharmaco-dynamics of vildagliptin in patients with type 2 diabetes mellitus. Clin Pharmacokinet, 46:577-88.
44. He YL, Wang Y, Bullock JM, et al. 2007e. Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT. J Clin Pharmacol, 47:633-41.
45. Hinke SA, Kuhn-Wache K, Hoffmann T, et al. 2002a. Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1. Biochem Biophys Res Commun, 291:1302-8.
46. Hinke SA, McIntosh CH, Hoffmann T, et al. 2002b. On combination therapy of diabetes with metformin and dipeptidyl peptidase IV inhibitors. Diabetes Care, 25:1490-1.
47. Kahn SE, Haffner SM, Heise MA, et al. 2006. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med, 355:2427-43.
48. Kahn SE, Prigeon RL, McCulloch DK, et al. 1993. Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function. Diabetes, 42:1663-72.
49. Kardas P. 2005. The DIACOM study (effect of DosIng frequency of oral Antidiabetic agents on the COMpliance and biochemical control of type 2 diabetes). Diabetes Obes Metab, 7:722-8.
50. Koro CE, Bowlin SJ, Bourgeois N, et al. 2004. Glycemic control from 1988 to 2000 among US adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care, 27:17-20.
51. Langley AK, Suffoletta TJ, Jennings HR. 2007. Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus. Pharmacotherapy, 27:1163-80.
52. Lau DT, Nau DP. 2004. Oral antihyperglycemic medication nonadherence and subsequent hospitalization among individuals with type 2 diabetes. Diabetes Care, 27:2149-53.
53. Lindsay JR, Duffy NA, McKillop AM, et al. 2005. Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes. Diabet Med, 22:654-7.
54. Mannucci E, Ognibene A, Cremasco F, et al. 2001. Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. Diabetes Care, 24:489-94.
55. Mari A, Sallas WM, He YL, et al. 2005. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell fanction inpatients with type 2 diabetes. J Clin Endocrinol Metab, 90:4888-94.
56. Mari A, Scherbaum WA, Nilsson PM, et al. 2007. Characterization of the influence of vildagliptin on model-assessed {beta}-cell function in patients with type 2 diabetes and mild hyperglycemia. J Clin Endocrinol Metab.
57. Matikainen N, Manttari S, Schweizer A, et al. 2006. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia, 49:2049-57.
58. Melikian C, White TJ, Vanderplas A, et al. 2002. Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin Ther, 24:460-7.
59. Migoya EM, Miller J, Larson P, et al. 2007. Sitagliptin, a selective DPP-4 inhibitor, and metformin have complementary effects to increase active GLP-1 concentrations. Diabetes, 56:A74.
60. Nathan DM, Buse JB, Davidson MB, et al. 2008. Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: Update regarding the thiazolidinediones. Diabetologia, 51:8-11.
61. Nathan DM, Buse JB, Davidson MB, et al. 2006. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 29:1963-72.
62. Nathan DM, Davidson MB, DeFronzo RA, et al. 2007. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care, 30:753-9.
63. Nichols GA, Alexander CM, Girman CJ, et al. 2006. Treatment escalation and rise in HbA1c following successful initial metformin therapy. Diabetes Care, 29:504-9.
64. Osterberg L, Blaschke T. 2005. Adherence to medication. N Engl J Med, 353:487-97.
65. Paes AH, Bakker A, Soe-Agnie CJ. 1997. Impact of dosage frequency on patient compliance. Diabetes Care, 20:1512-17.
66. Pi-Sunyer FX, Schweizer A, Mills D, et al. 2007. Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res Clin Pract, 76:132-8.
67. Pladevall M, Williams LK, Potts LA, et al. 2004. Clinical outcomes and adherence to medications measured by claims data in patients with diabetes. Diabetes Care, 27:2800-5.
68. Pratley RE, Rosenstock J, Pi-Sunyer FX, et al. 2007a. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care, 30:3017-22.
69. Pratley RE, Schweizer A, Rosenstock J, et al. 2007b. Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naive patients: analysis of pooled vildagliptin monotherapy database. Diabetes Obes Metab.
70. Rosenstock J, Baron MA, Camisasca RP, et al. 2007a. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab, 9:175-85.
71. Rosenstock J, Baron MA, Dejager S, et al. 2007b. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care, 30:217-23.
72. Rosenstock J, Foley JE, Rendell M, et al. 2007c Effects of the DPP-4 inhibitor vildagliptin on incretin hormones, islet function, and post-prandial glycemia in subjects with impaired glucose tolerance. Diabetes Care.
73. Schectman JM, Nadkarni MM, Voss JD. 2002. The association between diabetes metabolic control and drug adherence in an indigent population. Diabetes Care, 25:1015-21.
74. Scherbaum WA, Schweizer A, Mari A, et al. 2007. Efficacy and tolerability of vildagliptin in drug-naive patients with type 2 diabetes (T2DM) and mild hyperglycemia. Diabetes, 56:A134.
75. Schweizer A, Couturier A, Foley JE, et al. 2007. Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naive patients with Type 2 diabetes. Diabet Med, 24:955-61.
76. Stumvoll M, Nurjhan N, Perriello G, et al. 1995. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med, 333:550-4.
77. Sunkara G, Sabo R, Wang Y, et al. 2007. Dose proportionality and the effect of food on vildagliptin, a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers. J Clin Pharmacol, 47:1152-8.
78. Tahrani AA, Varughese GI, Scarpello JH, et al. 2007. Metformin, heart failure, and lactic acidosis: is metformin absolutely contraindicated? BMJ, 335:508-12.
79. Tourrel C, Bailbe D, Lacorne M, et al. 2002. Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4. Diabetes, 51:1443-52.
80. Turner RC, Cull CA, Frighi V, et al. 1999. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA, 281:2005-12.
81. Utzschneider KM, Tong J, Montgomery B, et al. 2008. The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose. Diabetes Care, 31:108-13.
82. Virally M, Blickle JF, Girard J, et al. 2007.Type 2 diabetes mellitus: epidemiology, pathophysiology, unmet needs and therapeutical perspectives. Diabetes Metab, 33:231-44.
83. Vella A, Bock G, Giesler PD, et al. 2007.Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes. Diabetes, 56:1475-80.
84. Zander M, Taskiran M, Toft-Nielsen MB, et al. 2001. Additive glucose-lowering effects of glucagon-like peptide-1 and metformin in type 2 diabetes. Diabetes Care, 24:720-5.